AXIM Biotechnologies manufacturing companion Empowered Diagnostics has submitted a revised Emergency Use Authorization to the US Food and Drug Administration for ImmunoPass, AXIM’s rapid check to establish Covid-19 neutralising antibodies at point-of-care. The updated software says that the test outcomes might be learn as qualitative.

• The current paper describes a lateral move assay that evaluates the levels of NAbs preventing the attachment of the viral receptor-binding…